DEUTERATED COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION

Title:

DEUTERATED COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION

Document Type and Number:

WIPO Patent Application WO/2023/147419

Kind Code:

A3

Abstract:

The compounds of the current disclosure include propynyl substituted indoles, where one or more hydrido radicals is substituted with a deuterium atom, wherein the compound binds a mutant p53 protein and increases wild-type p53 activity of the mutant p53 protein.

More Like This:

WO/2006/041961	ARYLTHIOINDOLE TUBULIN POLYMERIZATION INHIBITORS AND METHODS OF TREATING OR PREVENTING CANCER USING SAME
JP2002517460	[Title of Invention] β2-adrenergic receptor agonist
WO/2019/173877	OPHTHALMIC COMPOSITIONS, AND OCULAR USES THEREOF, OF INDIGO CARMINE

Inventors:

VU BINH (US)

Application Number:

PCT/US2023/061374

Publication Date:

September 07, 2023

Filing Date:

January 26, 2023

Export Citation:

Click for automatic bibliography generation Help

Assignee:

PMV PHARMACEUTICALS INC (US)

International Classes:

A61K31/404; A61K31/395; A61K31/416; A61K31/33

Domestic Patent References:

WO2021061643A1	2021-04-01
WO2021231474A1	2021-11-18

Other References:

TIMMINS GRAHAM S: "Deuterated drugs: where are we now?", EXPERT OPINION ON THERAPEUTIC PATENTS, TAYLOR & FRANCIS, GB, vol. 24, no. 10, 1 October 2014 (2014-10-01), GB , pages 1067 - 1075, XP093089945, ISSN: 1354-3776, DOI: 10.1517/13543776.2014.943184

Attorney, Agent or Firm:

SCHWAMB, Charles B. (US)

Download PDF:

View/Download PDF PDF Help

Previous Patent: PARP7 INHIBITORS

Next Patent: TRANSCATHETER HEART PROSTHESIS